305 abstracts found.



Making 3D possible: large scale organoid expansion using bioprocess design

Year:

Session type:

Theme:

Victoria Marsh Durban1,Mairian Thomas1,Kim Luetchford1,Trevor Dale1,Marianne Ellis1
1Cellesce Ltd

Investigating the anti-tumour effects of anti-PD-L1 immune checkpoint blockade combined with ionising radiation in the TrampC1 prostate cancer model.

Year:

Session type:

Theme:

Richard Bryant1,Yiannis Philippou1,Hanna Sjoberg1,Emma Murphy1,Said Alyacoubi1,Keaton Jones1,Alex Gordon-Weeks1,Gillies McKenna1,Uzi Gileadi1,Vincenzo Cerundolo1,Ian Mills1,Freddie Hamdy1,Ruth Muschel1
1University of Oxford

Excellent pathological complete response (pCR) rate with chemotherapy and dual anti-HER2 therapy in HER2 positive locally advanced breast cancer – the experience at Lincoln County Hospital

Year:

Session type:

Theme:

Rajeev Nair1,Michelle Kok Pei Ling1,Abhro Chaudhuri1
1Lincoln County Hospital

Optimizing Chemotherapy for Frail and Elderly Patients with Advanced Gastroesophageal Cancer (aGOAC): the GO2 Phase III Trial.

Year:

Session type:

Theme:

Peter Hall1,Daniel Swinson2,Simon Lord3,Helen Marshall4,David Cairns4,Sharon Ruddock4,Emma Batman4,Galina Velikova4,Russell Petty5,Justin Waters6,Jonathan Wadsley7,Stephen Falk8,Catherine Handforth9,Rajarshi Roy10,Mano Joseph11,Konstantinos Kamposioras12,Jonathan Nicoll13,Tania Tillett14,Sebastian Cummins15,Simon Grumett16,Zuzana Stokes17,Tom Waddell18,Anirban Chatterjee19,Angel Garcia20,Christine Allmark21,Matthew Seymour22
1University of Edinburgh, Edinburgh, UK,2Leeds Teaching Hospitals NHS Trust, Leeds, UK,3University of Oxford, Oxford, UK,4University of Leeds, Leeds, UK,5University of Dundee, Dundee, UK,6Kent Oncology Centre, Maidstone, UK,7Western Park Hospital, Sheffield, UK,8Bristol Haematology and Oncology Centre, Bristol, UK,9University of Sheffield, Sheffield, UK,10Castle Hill Hospital, Hull, UK,11The Royal Wolverhampton NHS Trust, Wolverhampton, UK,12Mid Yorkshire Hospitals NHS Trust, Wakefield, UK,13North Cumbria University Hospitals NHS Trust, Carlisle, UK,14Royal United Hospital Bath NHS Trust, Bath, UK,15Royal Surrey County Hospital NHS Foundation Trust, Guilford, UK,16The Dudley Group NHS Foundation Trust, Dudley, UK,17United Lincolnshire Hospitals NHS Trust, Lincoln, UK,18The Christie NHS Foundation Trust, Manchester, UK,19The Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK,20The Shrewsbury and Telford Hospital NHS Trust,21NCRI Consumer Forum, London, UK,22University of Leeds

Modulation of tumor microenvironment by targeting cancer associated fibroblasts in dendritic cell based immunotherapy

Year:

Session type:

Theme:

Sheefa Mirza1,Clement Penny1,Nayan Jain2,Rakesh Rawal2
1University of Witwatersrand,2Gujarat University

Treatment and survival in non-metastatic muscle invasive bladder cancer: analysis of a national patient cohort.

Year:

Session type:

Theme:

Joseph John1,Mohini Varughese2,Nicola Cooper3,Kwok Wong3,Luke Hounsome3,Sarah Treece4,Susan Harden5
1Taunton and Somerset NHS Foundation Trust, Taunton, UK,2Taunton and Somerset NHS Foundation Trust,3National Cancer Registration and Analysis Service, Public Health England,4North West Anglia NHS Foundation Trust,5Cambridge University Hospitals NHS Foundation Trust

Identification and validation of natural anti-drug resistant and anticancer stem cell agents in TNBC stem cells

Year:

Session type:

Theme:

Prem Kushwaha1,Shashank Kumar1
1Central University of Punjab, Punjab, India

Cell culture under perfusion conditions reduces cellular metabolic stress and mimics the in vivo physiological environment in pancreatic cancer

Year:

Session type:

Theme:

Daniel Hughes1,Frances Willenbrock2,Zahir Soonawalla3,Srikanth Reddy3,Michael Silva3,Somnath Mukherjee3,Eric O'Neill2
1University of Oxford, Oxford, UK,2Department of Oncology, University of Oxford, Oxford, UK,3Oxford University Hospitals, Oxford, UK

Time on treatment and treatment patterns in patients with metastatic colorectal carcinoma: a retrospective chart review

Year:

Session type:

Theme:

Anna Ryan1,Daniel Sugrue2,Michael Hurst2,Pratik Thakkar3,Sidonie Hartridge-Lambert3,Hamzeh Kayhanian1,Jason Gordon2,Manuel Rodriguez-Justo1,Kai-Keen Shiu1,Dionysios Ntais3
1University College London Hospital,2Health Economics and Outcomes Research Ltd.,3Bristol-Myers Squibb

Peer review for target volume quality assurance at Guy’s Cancer Centre.

Year:

Session type:

Theme:

Pippa Lewis1,Renee Steel1,Teresa Guerrero Urbano1,Kathryn Innes1,Imran Hussain1,Barbara Fuller1
1Guy's and St Thomas' NHS Foundation Trust

The road to personalised anticancer therapy: utilizing the LAT1 transporter as a selective mode of iron deprivation

Year:

Session type:

Theme:

Gina Abdelaal1,Kyriakou Sotirus1,David Tetard1,Stephany Veuger1
1Northumbria University

BEACON: A Randomised, Phase 3 Study of Encorafenib and Cetuximab +/- Binimetinib vs. Choice of Either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E–Mutant Metastatic Colorectal Cancer Patients

Year:

Session type:

Theme:

Harpreet Wasan1,Tobias Arkenau2,Mike Braun3,Leslie Samuel4,Janet Graham5,Scott Kopetz6,Axel Grothey7,Eric Van Cutsem8,Rona Yaeger9,Takayuki Yoshino10,Jayesh Desai11,Fortunato Ciardello12,Ashwin Gollerkeri13,Kati Maharry13,Victor Sandor13,Janna Christy-Bittel13,Lisa Anderson13,Josep Tabernero14
1Hammersmith Hospital, London, UK,2Sarah Cannon Research Institute, London, UK,3Manchester Academic Health Science Centre and The Christie NHS Foundation Trust, Manchester, UK,4Aberdeen Royal Infirmary, Aberdeen, UK,5Beatson West Of Scotland Cancer Centre, Glasgow, UK,6UT MD Anderson Cancer Center, Houston, US,7West Cancer Center, University of Tennessee, Knoxville, US,8University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium,9Memorial Sloan-Kettering Cancer Center, New York, US,10National Cancer Center Hospital East, Kashiwa, Japan,11Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia,12University of Campania, Caserta, Italy,13Array BioPharma Inc, Boulder, US,14Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain

TOPARP-B: A Phase II Randomised Trial of the Poly(ADP)-Ribose Polymerase (PARP) Inhibitor Olaparib for Metastatic Castration Resistant Prostate Cancers (mCRPC) with DNA Damage Repair (DDR) Alterations

Year:

Session type:

Theme:

Joaquin Mateo1,Nuria Porta2,Ursula McGovern3,Tony Elliott4,Robert Jones5,Isabel Syndikus6,Christy Ralph7,Suneil Jain8,Mohini Varughese9,Omi Parikh10,Simon Crabb11,Angus Robinson12,Duncan McLaren13,Alison Birtle14,Jacob Tanguay15,Susana Miranda2,George Seed2,Claudia Bertan2,Aude Espinasse2,Peter Chatfield2,Diletta Bianchini16,Emma Hall2,Suzanne Carreira2,Johann De Bono17
1Vall d’Hebron Institute of Oncology, Barcelona, Spain,2The Institute of Cancer Research, London, UK,3University College Hospital, London, UK,4The Christie Hospital, Manchester, UK,5The Beatson West of Scotland Cancer Centre, Glasgow,6The Clatterbridge Cancer Centre, Birkenhead, UK,7St James's University Hospital, Leeds, UK,8Belfast City Hospital, Belfast, UK,9Musgrove Park Hospital, Taunton, UK,10Royal Blackburn Hospital, Blackburn, UK,11Southampton General Hospital, Southampton, UK,12Royal Sussex County Hospital, Brighton, UK,13Western General Hospital, Edinburgh, UK,14Royal Lancaster Infirmary, Lancaster, UK,15Velindre Cancer Centre, Cardiff, UK,16The Royal Marsden NHS Foundation Trust, UK,17The Institute of Cancer Research, London, UK, London & The Royal Marsden NHS Foundation Trust, London, UK

Capivasertib plus fulvestrant versus placebo plus fulvestrant in metastatic ER positive breast cancer (FAKTION): A randomised, double-blind, placebo-controlled, phase II trial

Year:

Session type:

Theme:

Robert Jones1,Margherita Carucci2,Angela Casbard2,Rachel Butler3,Catherine Bale4,Fouad Alchami5,Pavel Bezecny6,Johnathan Joffe7,Sarah Moon8,Chris Twelves9,Ramachandran Venkitaraman10,Simon Waters1,Sacha Howell11
1Velindre University NHS Trust, Cardiff, UK,2Cardiff University, Cardiff, UK,3North Bristol NHS Trust, Bristol, UK,4Betsi Cadwaladr University Health Board, Bangor, UK,5Department of Cellular Pathology, University Hospital of Wales, Cardiff, UK,6Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK,7Royal College of Physicians of London, London, UK,8University Hospitals of Morecambe Bay NHS Trust, Milnthorpe Cumbria, UK,9University of Leeds and St. James's Institute of Oncology, Leeds, UK,10The Ipswich Hospital NHS Trust, Ipswich, UK,11The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK

Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in patients with metastatic colorectal cancer

Year:

Session type:

Theme:

Jamal Zekri1,Ehab Mosaad2,Refaei Belal Ibrahim3,Kamel Mohamed Kamal4,Adnan Hussain5,Mohammed Abbas Baghdadi6
1College of Medicine, Al-Faisal University, King Faisal Specialist Hospital (Jeddah),2Medical oncology department, National Cancer Institute, Cairo University,3Department of clinical oncology and nuclear medicine. Faculty of medicine Al Azhar University,4Cairo University,5King Faisal Specialist Hospital and Research Center- Jeddah,6Research Centre, King Faisal Specialist Hospital & Research Centre, Jeddah

Does recruitment to cancer clinical trials at the Leicester Royal Infirmary reflect the ethnic diversity of those receiving systemic anticancer therapy?

Year:

Session type:

Theme:

Adrian Nicholson1,Mohammed Karolia1,Emily de Groot2,Sarah Nicholson1,Devinder Dhillon1,Lynne Howells3,Harriet Walter3,Anne Thomas3
1University Hospitals Leicester, Leicester, UK,2University of Leicester Medical School, Leicester, UK,3Leicester Cancer Research Centre, Leicester, UK

Large scale expansion of patient-derived breast cancer organoids to transform drug discovery screening assays

Year:

Session type:

Theme:

Mairian Thomas1,Andrew Hollins2,Trevor Dale2,Marianne Ellis1
1Cellesce Ltd,2Cardiff University

Pathological Response and Cardiotoxicity Following Neoadjuvant Dual Anti-HER2 Therapy: Early Experience at a New Cancer Centre.

Year:

Session type:

Theme:

Adam Henry1,Gerard Walls1,Goudarz Mazdai1,Linda McLaughlin1,Lucy Jellett1,Rhun Evans2
1NHS (Western Health and Social Care Trust),2NHS (Western and Social Care Trust)

Orbital Tumor Board: lifesaver or timewaster?

Year:

Session type:

Theme:

Ayesha Butt1
1Aga Khan University Hospital

Assessment of the effect of oncolytic virotherapy in combination with cavitational ultrasound in the treatment of colorectal liver metastases using a precision cut tumour slice model

Year:

Session type:

Theme:

Marcos Kostalas1,Joshua Owen2,Claudia Hill2,Christopher Smith3,Nicola Annels3,Robert Carlisle2,Hardev Pandha3
1Royal Surrey County Hospital, Guildford, UK,2University of Oxford, Oxford, UK,3University of Surrey, Guildford, UK

18F-FDG-PET in Guided Dose-Painting with Intensity Modulated Radiotherapy in Oropharyngeal Tumours – Final Toxicity and Disease Outcomes of FiGaRO Phase I Multicentre Feasibility Study

Year:

Session type:

Theme:

Delali Adjogatse1,Andriana Michaelidou2,Yae-Eun Suh1,Lucy Pike2,Christopher Thomas3,Owain Woodley4,Beatriz Sanchez Nieto5,Tom Rackley6,Nachi Palaniappan6,Vetrisudar Jayaprakasam7,Mererid Evans6,Mary Lei1,Sally Barrington2,Teresa Guerrero Urbano1
1Dept of Oncology, Guy's and St Thomas NHS Foundation Trust, London, UK,2King's College London and Guy's and St Thomas PET Centre, London, UK, School of Biomedical Engineering and Imaging Sciences, King's College London, King's Health Partners, London, UK,3Department of Medical Physics, Guy's and St Thomas NHS Foundation Trust, London, UK, King's College London and Guy's and St Thomas' PET Centre, London, UK, School of Biomedical Engineering and Imaging Sciences, King's College London, King's Health Partners, London, UK,4Medical Physics Dept, Velindre University NHS Trust, Cardiff, UK,5Faculty of Physics, Pontificia Universidad Catolica de Chile, Santiago, Chile,6Dept of Oncology, Velindre University NHS Trust, Cardiff, UK,7Wales Research and Diagnostic PET Imaging Centre, Cardiff, UK

Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (MBM; CheckMate 204)

Year:

Session type:

Theme:

Hussein Tawbi1,Peter Forsyth2,F. Stephen Hodi3,Christopher Lao4,Stergios Moschos5,Omid Hamid6,Michael B. Atkins7,Karl Lewis8,Reena P. Thomas9,John A. Glaspy10,Sekwon Jang11,Alain Algazi12,Nikhil I. Khushalani2,Michael A. Postow13,Anna C. Pavlick14,Marc Ernstoff15,David A. Reardon3,Agnes Balogh16,Jasmine Rizzo16,Kim Margolin17
1University of Texas MD Anderson Cancer Center, Houston, US,2Moffitt Cancer Center and Research Institute, Tampa, US,3Dana-Farber Cancer Institute, Boston, US,4University of Michigan, Ann Arbor, US,5University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, US,6The Angeles Clinic and Research Institute, Los Angeles, US,7Georgetown Lombardi Comprehensive Cancer Center, Washington, US,8University of Colorado Comprehensive Cancer Center, Aurora, US,9Stanford University Hospital, Stanford, US,10Jonsson Comprehensive Cancer Center University of California, Los Angeles, US,11Inova Schar Cancer Institute, Falls Church, US, Virginia Commonwealth University, Richmond, US,12University of California–San Francisco, San Francisco, US,13Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, US,14New York University Langone Medical Center, New York, US,15Roswell Park Cancer Institute, Buffalo, US,16Bristol-Myers Squibb, New York, US,17City of Hope, Duarte, US

Safety and efficacy of 12 mg/d lenvatinib (LEN) in patients with unresectable hepatocellular carcinoma (uHCC) and bodyweight >80 kg in REFLECT

Year:

Session type:

Theme:

Arndt Vogel1,Masatoshi Kudo2,Ann-Lii Cheng3,Max W. Sung4,Richard S. Finn5,Albert Y. Lin6,Ghassan K. Abou-Alfa7,Angel Alsina8,Valeriy Breder9,Niall Tebbutt10,Pia Osterlund11,C. J. Yen12,Min Ren13,Soamnauth Misir13,Corina E. Dutcus13,Daniel Palmer14,Philippe Merle15,Matthias Pinter16,TR Jeffry Evans17
1Hannover Medical School,2Kindai University School of Medicine,3National Taiwan University Hospital,4Tisch Cancer Institute at Mount Sinai,5Geffen School of Medicine, UCLA Medical Center,6VA Palo Alto Health Care System,7Memorial Sloan Kettering Cancer Center,8Tampa General Hospital,9N.N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation,10Olivia Newton-John Cancer Centre,11Tampere University and Central Hospital,12National Cheng Kung University Hospital,13Eisai Inc.,14University of Liverpool, Liverpool,15CHU de Lyon -Hospital La Croix-Rousse,16Medical University of Vienna,17University of Glasgow

Xentuzumab (BI 836845), an IGF-neutralizing antibody, combined with exemestane and everolimus in hormone receptor-positive (HR+) locally advanced/metastatic breast cancer: Randomized Phase 2 results

Year:

Session type:

Theme:

John Crown1,Marie-Paule Sablin2,Javier Cortés3,Jonas Bergh4,Seock-Ah Im5,Yen-Shen Lu6,Noelia Martínez7,Patrick Neven8,Keun Seok Lee9,Serafín Morales10,J. Alejandro Pérez-Fidalgo11,Douglas Adamson12,Anthony Goncalves13,Aleix Prat14,Guy Jerusalem15,Laura Schlieker16,Rosa-Maria Espadero17,Thomas Bogenrieder18,Dennis Chin-Lun Huang19,Peter Schmid20
1St Vincent University Hospital, Dublin, Ireland,2Institut Curie, Paris, France,3IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain,4Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden,5Seoul National University Hospital, Seoul, South Korea,6National Taiwan University Hospital, Taipei, Taiwan,7IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain,8UZ Leuven, Campus Gasthuisberg, Lueven, Belgium,9National Cancer Center, Goyang, South Korea,10Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain,11Hospital Clinico Universitario Valencia, Spain, Biomedical Research Institute INCLIVA, Valencia, Spain, el Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain,12Tayside Cancer Centre, Ninewells Hospital, Dundee, UK,13Institut Paoli Calmettes, Marseille, France,14Hospital Clínic de Barcelona Servicio de Oncología Médica, Barcelona, Spain,15Centre Hospitalier Universitaire de Liège, Belgium, Liège University, Liège, Belgium,16External statistician on behalf of Boehringer Ingelheim Pharma GmbH & Co. KG, Bracknell, UK, Staburo GmbH & Co. KG. Staburo GmbH, Munich, Germany,17Boehringer Ingelheim España S.A, Barcelona, Spain,18Boehringer Ingelheim RCV, Vienna, Austria,19Boehringer Ingelheim Taiwan Limited, Taipei, Taiwan,20Centre for Experimental Cancer Medicine, Barts Cancer Institute, London, UK, Queen Mary University of London, London, UK

COPELIA: A Randomised Phase II Trial of Cediranib in Combination with Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy for Advanced Endometrial Cancer

Year:

Session type:

Theme:

Joanna Canham1,Gordon Jayson2,Robert Morgan2,Clare Freestone3,Angela Casbard4,Terri Kitson4,Alkesh Patel2,Chelsey Wheeler2,Rebecca Kristeleit5,Marcia Hall6,Louise Hanna7,Axel Walther8,Susana Banerjee9,Rene Roux10,Azmat Sadoyze11,Yvette Drew12,Andrew Clamp2
1WCTU, Cardiff University,2The Christie NHS Foundation Trust,3Centre For Trials Research,4Centre for Trials Research,5University College London,6Mount Vernon Hospital,7Velindre NHS Trust,8University Hospitals Bristol NHS Foundation Trust,9The Royal Marsden NHS Foundation Trust,10Oxford University Hospitals NHS Foundation Trust,11Greater Glasgow Health Board,12The Newcastle upon Tyne Hospitals NHS Foundation Trust

Adaptive Radiotherapy for Cancer of the Head and Neck guided by Intra-treatment ¹⁸F-FDG-PET and MRI scanning – Proposal for a Phase 1 feasibility study

Year:

Session type:

Theme:

Delali Adjogatse1,Andriana Michaelidou2,Yae-Eun Suh3,Lucy Pike2,Christopher Thomas4,Sally Barrington2,Lei Mary3,Teresa Guerrero Urbano3
1Dept of Oncology, Guy's and St Thomas NHS Foundation Trust, London, UK,2King's College London and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, King's Health Partners, London,3Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London,4King's College London and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, King's Health Partners, London AND Department of Medical Physics, Guy's and St Thomas' NHS Foundation Trust, London

Sulforaphane induces pyroptotic cell death via caspase signaling pathway in Hepatocellular Carcinoma (HCC): an alternative immuno-therapeutic approach

Year:

Session type:

Theme:

Kanipandian Nagarajan1,Deyu Li2,Dongxiao Li3
1Henan Provincial People’s Hospital/Henan University, Zhengzhou, China,2Henan Provincial People's Hospital, Zhengzhou, China,3Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Neo-epitopes/antigens discovery for cancer immunotherapy based treatment with precision oncology using advanced Artificial Intelligence

Year:

Session type:

Theme:

Jyothi Deva datta reddy1,Deva Reddy2,Dr.ram Reddy2,Samyukta Jyothi2
1Cancer moonshot @ www.cancermoonshot.in,2Cancermoonshot

Repurposing of niclosamide (a putative STAT3 inhibitor) to potentiate chemotherapeutic drugs in treating colorectal cancer

Year:

Session type:

Theme:

Mia Mingxia Wu1,Christy Wing Sum Tong1,Wei Yan1,Kenneth Kin Wah To1
1The Chinese University of Hong Kong

Safety and efficacy of 12 mg/d lenvatinib (LEN) in patients with unresectable hepatocellular carcinoma (uHCC) and bodyweight >80 kg in REFLECT

Year:

Session type:

Theme:

Arndt Vogel1,Masatoshi Kudo2,Ann-Lii Cheng3,Max W. Sung4,Richard S. Finn5,Albert Y. Lin6,Ghassan K. Abou-Alfa7,Angel Alsina8,Valeriy Breder9,Niall Tebbutt10,Pia Osterlund11,C. J. Yen12,Min Ren13,Soamnauth Misir13,Corina E. Dutcus13,Daniel Palmer14,Philippe Merle15,Matthias Pinter16,TR Jeffry Evans17
1Hannover Medical School,2Kindai University School of Medicine,3National Taiwan University Hospital,4Tisch Cancer Institute at Mount Sinai,5Geffen School of Medicine, UCLA Medical Center,6VA Palo Alto Health Care System,7Memorial Sloan Kettering Cancer Center,8Tampa General Hospital,9N.N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation,10Olivia Newton-John Cancer Centre,11Tampere University and Central Hospital,12National Cheng Kung University Hospital,13Eisai Inc.,14University of Liverpool, Liverpool,15CHU de Lyon -Hospital La Croix-Rousse,16Medical University of Vienna,17University of Glasgow

Recurrence rates after low dose radioiodine ablation for differentiated thyroid cancer within the NCRI HiLo trial.

Year:

Session type:

Theme:

Jon Wadsley1,Hakim-Moulay Dehbi2,Ujjal Mallick3,Kate Newbold4,Clive Harmer5,Allan Hackshaw2

1Weston Park Hospital,2University College London, UK,3Freeman Hospital, Newcastle upon Tyne, UK,4Royal Marsden Hospital, Sutton, UK,5Formerly of the Royal Marsden Hospital, Sutton


Evaluating the trade-offs men with localised prostate cancer make between the risks and benefits of treatments: The COMPARE study

Year:

Session type:

Theme:

Hashim U. Ahmed1,Verity Watson2,Neil McCartan3,Nicolas Krucien2,Victor Abu4,Divine Ikenwilo2,Mark Emberton3

1Imperial College London,2Health Economics Research Unit, University of Aberdeen,3Research Department of Urology, Division of Surgery and Interventional Science, Faculty of Medicine, University College London,4Health and Social Care, Adult Nursing, London South Bank University


10 year cancer centre experience of treating metastatic kidney cancer

Year:

Session type:

Theme:

Rachel Jones1,Jones Rachel2
1Weston Park Hospital,2Sheffield University

The effects of thrombocytopenia during treatment with first-line cisplatin/gemcitabine on survival in patients with advanced biliary tract cancer.

Year:

Session type:

Theme:

Laura Johnston1,Noor Ul-Ain-Tariq2,Clare Hodgson2,Angela Lamarca2,Richard Hubner2,Juan Valle2,Mairead McNamara2
1University of Manchester,2The Christie NHS Trust

Overcoming chemoresistance in osteosarcoma: the role of autophagy in cell death or survival following chemotherapy

Year:

Session type:

Theme:

Gabriel Rosa1,Beata Burczynska1,Britta Stordal1,Helen Roberts1
1Middlesex University

Do brain metastases affect the efficacy of Nivolumab in patients with metastatic renal cell carcinoma?

Year:

Session type:

Theme:

Dan Muller1,Matthew Wheater1
1University Hospital Southampton

Therapeutic potential of novel thiosemicarbazones in pediatric oncology: combined treatment with vinca alkaloids.

Year:

Session type:

Theme:

Silvia Chovanova1,Maria Krchniakova2,Petr Chlapek2,Jaroslav Sterba3,Des Richardson4,Renata Veselska5
1,2Department of Experimental Biology, Faculty of Science, Masaryk University, Brno; International Clinical Research Center, St. Anne's University Hospital, Brno,3Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno,4Molecular Pharmacology and Pathology Program, Department of Pathology and Bosh Institute, University of Sydney, Sydney,5Department of Experimental Biology, Faculty of Science, Masaryk University, Brno; International Clinical Research Center, St. Anne's University Hospital, Brno; Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno

Efficient elimination of B-lineage lymphomas using sortase A-generated site-specific anti-CD20-MMAE conjugates

Year:

Session type:

Theme:

Wen-bin Zhao1,Li-qiang Pan2,Wen-hui Liu1,Shu-qing Chen1
1Zhejiang university,2Harvard Medical School

Effectiveness and toxicity of EGFR-TKIs in elderly patients with EGFR-mutation positive NSCLC

Year:

Session type:

Theme:

Will Ince1,Saif Ahmad2,Stephanie Brown1,Matija Tausan1,Zacharias Tasigiannopoulos1,Konstantinos Geropantas1,Pinelopi Gkogkou1
1Norfolk and Norwich University Hospital,2Norfolk and Norwich

Real world experience of upfront docetaxel in metastatic hormone‑sensitive prostate cancer: a 4-year multi-centre review

Year:

Session type:

Theme:

James Bennett1,Claudia Ajayi1,Daniel Muller1,Jemma Longley1,Asfandyar Yousuf1,Ana Silva1,Chloe Holden2,Matthew Roberts3,Susannah Brock3,Simon Crabb1,Caroline Chau2
1University Hospital Southampton NHS Foundation Trust,2Portsmouth Hospitals NHS Trust,3Poole Hospital NHS Foundation Trust

Use of Theoretical Domains Framework to identify psychosocial determinants associated with adjuvant hormonal treatment adherence among breast cancer population: mixed method systematic review

Year:

Session type:

Theme:

Haley Ong1,Christine Campbell1,David Weller1
1University of Edinburgh

Patterns of post-mastectomy radiotherapy in patients with immediate breast reconstruction – Results from the iBRA-2 (immediate Breast Reconstruction and Adjuvant therapy) prospective cohort study

Year:

Session type:

Theme:

Tim Rattay1,Rachel O'Connell2,Rajiv Dave3,Matthew Gardiner4,Adam Trickey5,Chris Holcombe6,Shelley Potter5
1University of Leicester,2Royal Marsden Hospital,3University Hospitals of South Manchester,4University of Oxford,5University of Bristol,6Royal Liverpool and Broadgreen University Hospitals NHS Trust

PERSEPHONE: A randomised phase 3 non-inferiority trial of 6 versus 12 months (m) of adjuvant trastuzumab in patients with HER2 positive (+) early breast cancer (EBC)

Year:

Session type:

Theme:

Helena Earl1,Louise Hiller2,Anne-Laure Vallier1,Shrushma Loi3,Donna Howe2,Helen Higgins2,Karen McAdam1,Luke Hughes-Davies1,Adrian Harnett4,Mei-Lin Ah-See5,Richard Simcock6,Daniel Rea7,Janine Mansi8,Jean Abraham1,Carlos Caldas1,Claire Hulme9,David Miles5,Andrew Wardley10,David Cameron11,Janet Dunn2
1Cambridge University Hospitals,2University of Warwick,3University of Birmingham,4Norfolk and Norwich University Hospital,5Mount Vernon Cancer Centre,6Royal Sussex County Hospital,7Sandwell and West Birmingham Hospitals NHS Trust,8Guy's Hospital,9University of Leeds,10Christie Research Facility,11University of Edinburgh

PEARL: PET-based Adaptive Radiotherapy Clinical Trial

Year:

Session type:

Theme:

Martina Svobodova1,Sarah Hargreaves2,John Staffurth2,Max Robinson3,Rachel Butler4,Emiliano Spezi5,Rhydian Maggs2,Owain Woodley2,Vetri Jayaprakasam2,Chris Hurt1,Mererid Evans2,Thomas Rackley2
1Centre for Trials Research, Cardiff University,2Velindre Cancer Centre,3Royal Victoria Infirmary, Newcastle,4All Wales Genetics Laboratory, Cardiff and Vale Health Board,5School of Engineering, Cardiff University

No treatment field recurrence after Intra-Operative Electron Beam Radiotherapy (IOERT) for advanced and recurrent abdomino-pelvic cancers: Feasibility, safety, and medium term outcomes in a UK setting

Year:

Session type:

Theme:

Sheah Lin Lee1, Gui Han Lee2Rahul Bhome1,Kathryn Donovan2,Gillian Ansell2,Julian Smith2,Neil Pearce2,Adly Naga2,Claire Birch2,Andrew Bateman2, Alex Mirnezami2

1University of Southampton,2University Hospital Southampton


The LISTER feasibilty trial: A feasibility randomised controlled trial of Lugol’s iodine in the surgical treatment of oral and oropharyngeal Epithelial Dysplasia

Year:

Session type:

Theme:

Jim McCaul1,Stuart Hislop2,Abdul Ahmed3,Paul Norris4,Kishore Shekar5,Panos Kyzas6,David Sutton7,Rahul Jayaram3,Jacquline Quantrill8,Max Robinson9,Jeremy McMahon10
1Queen Elizabeth University Hospital,2Crosshouse Hospital, Kilmarnock,3Northwick Park Hospital,4Queen Victoria Hospital, East Grinstead,5Ninewells Hospital Dundee,6Pennine Acute NHS Trust,7Bradford Teaching Hospitals NHS Foundation Trust,8Bradford Institute for Health Research,9University of Newcastle,10Queen Elizabeth University Hospital, Glasgow

Automated brachytherapy seed counting with multimodal image registration on trained deep learning convolutional neural network

Year:

Session type:

Theme:

Rollo Moore1,Rollo Moore1,Ladislav Urban2,Yae-eun Suh3,Kate Roberts4,Derfel Ap Dafydd1,Vincent Khoo1
1The Royal Marsden NHS Foundation Trust,2Dynocortex,3The Royal Marsden Hospital NHS Trust,4The Royal Marsden NHS Trust

Arrayed CRISPR library screen to identify synthetic lethal partners of the histone methyltransferase KMT2D in diffuse large B cell lymphoma

Year:

Session type:

Theme:

Elizabeth Blaikley1,Mark Cockerill1,Cath Eberlein1,Ben Hodgson1,Graeme Walker1,Caroline Springer1
1CRUK Manchester Institute

Vismodegib for the treatment of locally advanced BCC – The East of England experience

Year:

Session type:

Theme:

David Maskell1,Dr Stephanie Browne2,Jenny Nobes2,Marc Moncrieff2,Amer Durrani3,Kate Fife3
1NHS,2Norfolk and Norwich University Hospital Foundation Trust,3Cambridge University Hospitals

Betulinic acid-doxorubicin drug combination synergistically supresses cell viability and enhances apoptotic death in acute myeloid leukaemia cell lines by increasing Bax/Bcl-2 ratio

Year:

Session type:

Theme:

Milan Vu1,Milan Vu2,Nick Kassouf2,Celia Bell2,Sandra Appiah2
1middlesex University,2Middlesex University